AcSé crizotinib, un essai pionnier du programme AcSé dans le champ de la médecine personnalisée (in partie IV : Soutenir l’innovation scientifique en cancérologie)

G. Vassal

doi:10.1007/s10269-014-2432-9

AcSé crizotinib, un essai pionnier du programme AcSé dans le champ de la médecine personnalisée (in partie IV : Soutenir l’innovation scientifique en cancérologie)

G. Vassal

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

The AcSé crizotinib project is the first clinical trial of the AcSé program (for “secure access to innovative targeted therapies”) developed by the French National Cancer Institute. This trial aims to offer cancer patients, for whom validated therapies have failed, access to this targeted therapy, based on a molecular abnormality of their tumour.

Titre traduit de la contribution	AcSé crizotinib, a pioneering trial of the AcSé programm in the field of personalized medicine (in part IV: Supporting scientific innovation in oncology)
langue originale	Français
Pages (de - à)	61-62
Nombre de pages	2
journal	Oncologie
Volume	16
Numéro de publication	1
Les DOIs	https://doi.org/10.1007/s10269-014-2432-9
état	Publié - 21 sept. 2014

mots-clés

Adults and children
Clinical trial
Crizotinib
Equal access
French territoty
Molecular alterations
Molecular testing
Off-label
Parternship
Personalized medicine
Secure access
Targeted therapies

Accès au document

10.1007/s10269-014-2432-9

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d86941e319114eea95e1c2e303541cb3,

title = "AcS{\'e} crizotinib, un essai pionnier du programme AcS{\'e} dans le champ de la m{\'e}decine personnalis{\'e}e (in partie IV : Soutenir l{\textquoteright}innovation scientifique en canc{\'e}rologie)",

abstract = "The AcS{\'e} crizotinib project is the first clinical trial of the AcS{\'e} program (for “secure access to innovative targeted therapies”) developed by the French National Cancer Institute. This trial aims to offer cancer patients, for whom validated therapies have failed, access to this targeted therapy, based on a molecular abnormality of their tumour.",

keywords = "Adults and children, Clinical trial, Crizotinib, Equal access, French territoty, Molecular alterations, Molecular testing, Off-label, Parternship, Personalized medicine, Secure access, Targeted therapies",

author = "G. Vassal",

note = "Publisher Copyright: {\textcopyright} 2014, Springer-Verlag France.",

year = "2014",

month = sep,

day = "21",

doi = "10.1007/s10269-014-2432-9",

language = "Fran{\c c}ais",

volume = "16",

pages = "61--62",

journal = "Oncologie",

issn = "1292-3818",

number = "1",

}

TY - JOUR

T1 - AcSé crizotinib, un essai pionnier du programme AcSé dans le champ de la médecine personnalisée (in partie IV : Soutenir l’innovation scientifique en cancérologie)

AU - Vassal, G.

PY - 2014/9/21

Y1 - 2014/9/21

N2 - The AcSé crizotinib project is the first clinical trial of the AcSé program (for “secure access to innovative targeted therapies”) developed by the French National Cancer Institute. This trial aims to offer cancer patients, for whom validated therapies have failed, access to this targeted therapy, based on a molecular abnormality of their tumour.

AB - The AcSé crizotinib project is the first clinical trial of the AcSé program (for “secure access to innovative targeted therapies”) developed by the French National Cancer Institute. This trial aims to offer cancer patients, for whom validated therapies have failed, access to this targeted therapy, based on a molecular abnormality of their tumour.

KW - Adults and children

KW - Clinical trial

KW - Crizotinib

KW - Equal access

KW - French territoty

KW - Molecular alterations

KW - Molecular testing

KW - Off-label

KW - Parternship

KW - Personalized medicine

KW - Secure access

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84938211593&partnerID=8YFLogxK

U2 - 10.1007/s10269-014-2432-9

DO - 10.1007/s10269-014-2432-9

M3 - Article

AN - SCOPUS:84938211593

SN - 1292-3818

VL - 16

SP - 61

EP - 62

JO - Oncologie

JF - Oncologie

IS - 1

ER -